Kenvue stock has recently seen its consensus analyst price target decrease modestly from $21.70 to $20.63. This slight adjustment reflects a mix of new insights, as analysts weigh fresh legal and reputational risks against potential value opportunities from strategic changes. Stay tuned to discover how investors and observers can best monitor the evolving narrative around Kenvue in the coming months.

The past several weeks have brought a flurry of updates from Wall Street analysts regarding Kenvue, many of which reflect both optimism for the company's long-term potential and concerns about ongoing legal and reputational headwinds. Below is a summary of the most notable perspectives from major research firms.

???? Bullish Takeaways

BofA reiterated its Buy rating, stating that Kenvue's post-selloff valuation has created a "particularly attractive entry point" for investors, with a discounted price relative to household and personal care peers. The firm's price target is set at $21, recently lowered from $25, reflecting adjusted sector-wide estimates but continued confidence in Kenvue's execution and the achievability of new guidance.

Rothschild & Co Redburn upgraded Kenvue to Buy, emphasizing a now "clear path to value creation" as the company's strategic review unfolds. The firm highlights the significant trading discount to its sum-of-the-parts valuation (over 40%) and views recent regulatory developments as less severe than initially feared. Their target stands at $22.

Despite concerns around Tylenol, Evercore ISI notes that the recent share selloff might be overdone, arguing that the lack of causal scientific evidence for alleged product risks could limit any long-term impact. The analyst acknowledges the premium commanded by Tylenol within Kenvue's portfolio and has set a revised price target of $23.

Analysts reward Kenvue's management for recent transparency, cost control measures, and strategic responsiveness, especially in light of recent headline risks and reset financial guidance.

???? Bearish Takeaways

Citi has turned increasingly cautious, reiterating a Neutral rating and reducing its price target from $22 to $17. The analyst cited emerging legal risks outside the U.S. and Canada related to the talc litigation in the UK and lingering uncertainties from earlier U.S. cases against Johnson & Johnson, noting these could weigh on sentiment and lead to near-term volatility.

Barclays lowered its price target to $17 and maintained an Equal Weight rating, flagging "muted and decelerating" growth across key personal care categories as a concern for Kenvue's topline momentum.

Evercore ISI reduced its target to $18 (from $23 previously) citing new regulatory scrutiny on Tylenol, a vital driver of Kenvue's revenues. The firm points to increased headline and reputational risks and the potential for shifts in consumer behavior, though it maintains an In Line rating.

RBC Capital highlighted that while legal threats to Tylenol have not yet proven causation in court, the risk of continued litigation and media attention could cap near-term valuation upside.

Many firms are closely monitoring both valuation and execution quality, with some cautioning that risks from high-profile legal issues and regulatory developments may still not be fully reflected in the stock price.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Johnson & Johnson and Kenvue are facing their first UK lawsuits alleging that their talc-based products caused cancer. More than 3,000 claimants are involved in what could become a major legal battle.

Citi analysts have issued a cautious outlook for Kenvue following the UK talc litigation. They highlight the potential for legal liabilities outside the US and Canada while maintaining a Neutral rating and a $17 price target.

The Trump Administration is preparing to issue warnings to pregnant women against the use of Tylenol, citing unproven links to autism. This move comes despite significant opposition from Kenvue and skepticism from scientific advisers who note a lack of causal evidence.

Kenvue has announced a new strategic partnership with Albert Invent, aiming to utilize artificial intelligence to enhance its global research and development efforts across its brand portfolio.

The consensus analyst price target has decreased modestly from $21.70 to $20.63.

The discount rate has edged up slightly, rising from 8.24% to 8.27%.

Revenue growth expectations have dipped marginally from 2.55% to 2.54%.

Net profit margin has eased fractionally, moving from 13.09% to 13.07%.

The future P/E ratio has declined from 24.78x to 23.61x, which suggests expectations for a lower valuation multiple.

Narratives are a smarter, interactive way to invest. Think of them as living stories investors create by linking a company’s business trends to future forecasts and a fair value. Narratives on Simply Wall St’s Community page bring together numbers and insights, helping you spot when to buy or sell by watching how the company’s story unfolds alongside its price. New information is always integrated, so these narratives keep you ahead as events happen.

Head over to the Simply Wall St Community and follow the original Narrative on Kenvue to keep up to date on:

Why enhanced digital capabilities and operational streamlining could strengthen market share and boost cost efficiency for Kenvue

How a focus on innovation and emerging markets aims to deliver long-term expansion and premium pricing

The latest analyst expectations for future earnings, margins, and the risks that could reshape Kenvue’s financial outlook

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KVUE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com